BVS at a glance
Bioventus Inc. (BVS, SEC CIK 1665988) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 5, 2026 and Form 4 insider filings as recently as June 4, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Bioventus Inc. (BVS) reported revenue of $568.1 million (down 0.9% from FY2024) and net income of $22.7 million. Diluted EPS was $0.33.
- As of June 30, 2026, 26 institutional investment managers tracked by SignalX reported holding Bioventus Inc. (BVS) shares worth $121.3 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $568.1M
- −0.9% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 26 funds
- $121.3M · −2 vs prior quarter
- Latest 8-K
- Aug 5, 2026
- Item 2.02 · Item 8.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 27, 2026
Management Discussion & Analysis
- Quarterly revenue $153.2M, up $5.5M or 3.8% YoY
- Operating margin 12.5% vs 12.4%; gross margin 69.0% vs 69.1% YoY
- Best performer U.S. Pain Treatments, revenue $72.7M, up 12.8%; worst Surgical Solutions, down 4.7% to $43.6M
- $20.0M discretionary term-loan prepayment; $98.4M revolver capacity available
- Strategic alternatives review underway; no timetable or transaction assurance disclosed
Risk Factors
- New strategic-alternatives review risk triggered by August 2026 unsolicited acquisition proposal and other indications of interest
- Transaction uncertainty risk, including possible failure to complete a deal due to regulatory approvals, market conditions, or financing availability
- Operational disruption risk from time-consuming review activities, distraction, and potential loss of business opportunities
- Legal risk from potentially costly and time-consuming litigation related to the strategic-alternatives process
- Market risk from speculation, with potential significant common-stock price fluctuations
AI summary of the BVS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q2 and first-half 2026 financial results announced for period ended June 27, 2026
- Press release furnished as Exhibit 99.1, containing the detailed operating and financial results
Item 8.01: Other Events
- Independent director committee reviewing sale and standalone alternatives after unsolicited acquisition proposal and multiple expressions of interest
- No timetable established, with no assurance the review produces a transaction or strategic outcome
Item EX-99.1: Item EX-99.1
- Q2 revenue $153.2M, up 4%; Pain Treatments led growth at $81.7M, up 11.5%
- GAAP EPS $0.47 versus $0.11; net income benefited from removing a $24.6M deferred-tax valuation allowance
Item 5.07: Submission of Matters to a Vote of Security Holders
- 75,279,174 shares voted, representing 90.23% of outstanding voting shares
- All 12 director nominees elected through the 2027 annual meeting
Item 7.01: Regulation FD Disclosure
- FDA reclassified Exogen and similar stimulators from Class III to Class II on April 16, 2026
- CMS billing and Medicare fee schedule changes take effect May 18, 2026 for HCPCS E0747, E0748, and E0760
AI summaries of BVS 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for BVS
Don't miss the next BVS filing
- Alerts as it files. A push when BVS files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut BVS, by share count.
- Ask anything. An AI agent that reads every BVS filing and answers with sources.
BVS alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Bartholdson John A. | A | Jun 3, 2026 | 25,146 | - |
| SUTTER MARTIN P | A | Jun 3, 2026 | 25,146 | - |
| Ladone Mary Kay | A | Jun 3, 2026 | 25,146 | - |
| STALNECKER SUSAN M | A | Jun 3, 2026 | 25,146 | - |
| NEELS GUIDO J | A | Jun 3, 2026 | 25,146 | - |
| NOHRA GUY P | A | Jun 3, 2026 | 25,146 | - |
| McMurry-Heath Michelle | A | Jun 3, 2026 | 25,146 | - |
| Cowdy Philip G. | A | Jun 3, 2026 | 25,146 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $573.3M | $568.1M |
| Gross Profit | - | $388.2M | $388.2M |
| Operating Income | - | -$12.0M | $54.0M |
| Net Income | - | -$33.5M | $22.7M |
| Gross Margin | - | 67.7% | 68.3% |
| Op. Margin | - | -2.1% | 9.5% |
| Net Margin | - | -5.9% | 4.0% |
| Balance Sheet | |||
| Total Assets | $810.9M | $728.0M | $683.6M |
| Equity | - | $147.9M | $184.1M |
| ROE | - | -22.7% | 12.3% |
| Per Share | |||
| EPS | - | $-0.52 | $0.33 |
| Cash Flow | |||
| Operating CF | - | $38.8M | $74.7M |
| CapEx | $7.4M | $1.0M | $2.6M |
Source: XBRL data in Bioventus Inc. (BVS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate BVS share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 26 | $121.3M |
| Q1 2026 | 28 | $104.5M |
| Q4 2025 | 24 | $85.9M |
| Q3 2025 | 24 | $75.8M |
| Q2 2025 | 24 | $77.7M |
| Q1 2025 | 22 | $77.5M |
| Q4 2024 | 18 | $73.2M |
| Q3 2024 | 16 | $44.5M |
- BlackRock+302.4K (+10%)
- Dimensional Fund Advisors+255.3K (+29%)
- Renaissance Technologies LLC+246.5K (+50%)
- Prudential Financial+200.7K (+104%)
- Millennium Management+186.9K (+1124%)
- D.E. Shaw & Co−263.3K (-85%)
- Morgan Stanley−65.1K (-25%)
- Bank of America Corp−38.4K (-45%)
- Two Sigma Investments−28.4K (-11%)
- Franklin Resources−25.1K (-45%)
- Citadel Advisors LLC−17.1K
- U.S. Bancorp−51
Source: 13F-HR filings on SEC EDGAR (aggregated from 182 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
BVS filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Aug 5, 2026 | Jun 27, 2026 | Analysis | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| SC 13G | Jul 27, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 8-K | Jun 4, 2026 | - | Analysis | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 8-K | May 21, 2026 | - | Analysis | |
| 8-K | May 6, 2026 | - | Analysis | |
| 10-Q | May 6, 2026 | Mar 28, 2026 | Analysis | |
| 4 | Apr 14, 2026 | - | - | - |
| 4 | Apr 14, 2026 | - | - | - |
| 4 | Apr 14, 2026 | - | - | - |
| 4 | Apr 14, 2026 | - | - | - |
| 4 | Apr 14, 2026 | - | - | - |
| 4 | Mar 24, 2026 | - | - | - |
| 4 | Mar 17, 2026 | - | - | - |
| 4 | Mar 17, 2026 | - | - | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
BVS SEC filings: frequently asked questions
Which institutions hold BVS stock?
As of June 30, 2026, the largest Bioventus Inc. (BVS) holders among the 13F filers tracked by SignalX were BlackRock ($32.4 million), Vanguard Capital Management LLC ($16.5 million), Dimensional Fund Advisors ($10.7 million), State Street Corp ($10.4 million), Vanguard Portfolio Management LLC ($9.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was BVS's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Bioventus Inc. (BVS) reported revenue of $568.1 million (down 0.9% from FY2024) and net income of $22.7 million. Diluted EPS was $0.33. The figures come from the XBRL data in the 10-K.
What did BVS report in its latest 8-K?
Bioventus Inc. (BVS) filed an 8-K on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 8.01 (Other Events). Q2 and first-half 2026 financial results announced for period ended June 27, 2026.
What are the latest BVS SEC filings?
Bioventus Inc. (BVS) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 5, 2026 and a Form 4 insider filing on June 4, 2026.
What is BVS's SEC CIK number?
Bioventus Inc. (BVS)'s SEC Central Index Key (CIK) is 1665988. EDGAR lists every BVS filing under that number.
Ask anything about BVS
The research agent reads BVS's filings, financials, insider trades and 13F holders, then answers with sources.